Under construction – not a live service
Sign in
Not yet taking people in ChinaNo phase

Pomalidomide with an anti-CD20 antibody and prednisone for first treatment of indolent B-cell lymphoma

Tests pomalidomide, an antibody and prednisone in adults with newly diagnosed indolent lymphoma.

Key facts

Who runs it
The First Affiliated Hospital of Soochow University
Where
Suzhou, ChinaSee the site
Trial code
Registry title
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
Status
Not yet recruiting
People taking part
30 people, planned
Started
1 May 2026
Expected to end
31 Dec 2027
Type of study
Observational
Treatments tested
  • Pomalidomide
Record updated
27 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an indolent B-cell lymphoma who have not yet had any treatment and need treatment now.

Age
18 years or older.
Sex
Men and women can join.
Disease stage
Follicular lymphoma, CD20-positive marginal zone lymphoma, indolent mantle cell lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, or lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia. The disease must need treatment.
Earlier treatment
No earlier systemic anti-cancer treatment for the lymphoma.
Biomarker or test result
Marginal zone lymphoma must be CD20-positive.

Main reasons for not taking part

  • Another cancer in the past 5 years, unless treated with no sign of return
  • Lymphoma in the central nervous system, or change into a faster-growing lymphoma
  • Severe or uncontrolled infection
  • Major surgery in the past 30 days
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Age ≥ 18 years, regardless of sex
  • Confirmed diagnosis of follicular lymphoma (FL), or histopathologically confirmed CD20-positive marginal zone lymphoma (MZL), including extranodal marginal zone lymphoma (MALT), splenic marginal zone lymphoma (SMZL), and nodal marginal zone lymphoma (NMZL),or confirmed diagnosis of indolent mantle cell lymphoma (MCL)
  • Patients with a confirmed diagnosis of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
  • Confirmed diagnosis of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia
  • Presence of indications for treatment of indolent B-cell lymphoma
  • No prior systemic antitumor therapy for lymphoma
  • ECOG-PS score 0-2
  • Essentially normal bone marrow hematopoietic function, with routine blood tests as follows: white blood cell count >3000/uL, absolute neutrophil count ≥1.5 × 10\^9/L (use of granulocyte colony-stimulating factor is allowed), platelet count ≥75 × 10\^9/L (transfusion to reach this minimum platelet count is allowed), and hemoglobin ≥9.0 g/dL (prior red blood cell transfusion or use of recombinant human erythropoietin is allowed). If peripheral blood abnormalities are caused by lymphoma involvement of the bone marrow or spleen, neutrophils≥1.0 × 10\^9/L and platelets≥50 × 10\^9/L are acceptable (the investigator may determine at his/her discretion whether enrollment is appropriate)
  • Normal function of major organs:; Hepatic function: serum bilirubin ≤2.0 × ULN; serum ALT and AST ≤2.5 × ULN; Renal function: creatinine clearance >30 mL/min
  • Expected survival≥3 months as judged by the investigator; Voluntary written informed consent signed before trial screening

Who cannot take part

  • Major surgery within the past 30 days (excluding lymph node biopsy)
  • Current or prior other malignancy, unless curative treatment has been performed and there has been no evidence of recurrence or metastasis within the past 5 years
  • Other serious medical conditions that would affect this study (e.g., uncontrolled diabetes, gastric ulcer, or other serious cardiopulmonary diseases). The investigator has the authority to make this determination
  • Severe or uncontrolled infection
  • Allergy to the study drug; Patients considered unsuitable for enrollment by the investigator
  • Hepatic or renal dysfunction unrelated to lymphoma: alanine aminotransferase (ALT) >3 times the upper limit of normal, aspartate aminotransferase (AST) >3 times the upper limit of normal, total bilirubin (TBIL) >2 times the upper limit of normal, or serum creatinine >1.5 times the upper limit of normal
  • Lymphoma involvement of the central nervous system or transformation to a higher-grade lymphoma
  • Clinically manifest central nervous system dysfunction
  • Pregnant or lactating women, or women of childbearing potential who have not used contraceptive measures

Where in China

  • The First Affiliated Hospital of Soochow UniversitySuzhou, ChinaContact: Haiwen HuangNo longer taking part

About the trial

What the trial wants to find out

A Phase II Study of Pomalidomide Combined with Anti-CD20 Monoclonal Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma Objective: This prospective, single-arm, Phase II trial aims to evaluate the efficacy and safety of first-line pomalidomide plus anti-CD20 antibody and prednisone in patients with indolent B-cell lymphoma.

Read full original descriptionShow less

Study Population: Approximately 30 adult patients (age ≥18 years) will be enrolled. Eligible histologies include follicular lymphoma (FL), CD20-positive marginal zone lymphoma (MZL: extranodal MALT, splenic SMZL, nodal NMZL), indolent mantle cell lymphoma (MCL), chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. Patients must be treatment-naïve, have an indication for systemic therapy, ECOG performance status 0-2, and adequate bone marrow reserve (ANC ≥1.5×10⁹/L, platelets ≥75×10⁹/L, hemoglobin ≥9.0 g/dL; lower thresholds permitted if marrow/spleen involvement, per investigator discretion). Adequate organ function is required: bilirubin ≤2×ULN, ALT/AST ≤2.5×ULN, and creatinine clearance >30 mL/min. Life expectancy must be ≥3 months, and written informed consent is mandatory.

Exclusion Criteria: Patients are excluded if they have another malignancy within 5 years (unless curatively treated without recurrence), CNS lymphoma involvement, transformation to high-grade lymphoma, uncontrolled infection, severe comorbidities affecting study participation, significant non-lymphoma-related organ dysfunction (ALT/AST >3×ULN, bilirubin >2×ULN, creatinine >1.5×ULN), active CNS dysfunction, major surgery within 30 days, pregnancy or lactation, lack of contraception in women of childbearing potential, known drug hypersensitivity, or any condition deemed unsuitable by the investigator.

Treatment Regimen: Induction consists of six 28-day cycles. Anti-CD20 antibody is administered at 375 mg/m² weekly during Cycle 1 and on Day 1 of Cycles 2-6. Pomalidomide is given at 4 mg/day on Days 2-22 of Cycles 1-6. Prednisone is administered at 100 mg/day on Days 1-5 of Cycles 1-6. Maintenance therapy continues for 2 years with pomalidomide 4 mg/day on Days 1-14 and anti-CD20 antibody 375 mg/m² on Day 1 every 8 weeks.

Endpoints: The primary endpoint is overall response rate (ORR). Secondary endpoints include complete response rate (CR), progression-free survival (PFS), overall survival (OS), and safety (hematologic and non-hematologic adverse events).

Statistical Methods: Continuous variables will be summarized with descriptive statistics; categorical variables with frequencies and percentages. Time-to-event endpoints (PFS, OS, and duration of response) will be analyzed using the Kaplan-Meier method, reporting medians, quartiles, and 90% confidence intervals, along with event and censoring counts. ORR will be tested statistically and reported with a 90% confidence interval.

Timeline: The study is expected to begin in January 2026, complete enrollment by December 2026, and conclude by December 2027. The total planned sample size is 30 patients.

The group in the trial

  • Pomalidomide Combined with Anti-CD20 Monoclonal Antibody and Prednisone

    Treatment: Pomalidomide

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma: A Prospective, Multicenter, Phase II Study
Plain-language title
Pomalidomide with an anti-CD20 antibody and prednisone for first treatment of indolent B-cell lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
27 May 2026